

GLOSSARY OF TECHNICAL TERMS

In this document, unless the context otherwise requires, explanations and definitions of certain terms used in this document in connection with our Group and our business shall have the meanings set out below. The terms and their meanings may not correspond to standard industry meaning or usage of these terms.

“AAP”	American Academy of Pediatrics
“ADC”	antibody-drug conjugate
“ADHD”	Attention Deficient Hyperactivity Disorder, one of the most common neurodevelopmental disorders in children, which is characterized by symptoms such as difficulty paying attention, difficulty controlling impulsive behavior and being overly active
“AE”	adverse event, which may be mild, moderate, or severe, any untoward medical occurrence in a patient or subject receiving a drug or other pharmaceutical product in a clinical trial and which does not necessarily have a causal relationship with the treatment
“API”	active pharmaceutical ingredient, the active ingredient which is contained in a drug
“BID”	twice a day
“CAGR”	compound annual growth rate
“CCl ₄ ”	carbon tetrachloride
“CDMO”	contract development and manufacturing organization
“C _{max} ”	maximum plasma concentration, a pharmacokinetic parameter that measures the highest concentration of a drug in the blood, cerebrospinal fluid, or target organ after a dose is given
“CMC”	Chemistry, Manufacturing and Control
“COPD”	chronic obstructive pulmonary disease, a type of obstructive lung disease characterized by long-term breathing problems and poor airflow
“CRO”	contract research organization, a company that provides support to pharmaceutical companies by providing a range of professional research services on a contract basis
“CTA”	clinical trial application, a submission to the competent national regulatory authority for obtaining authorization to conduct a clinical trial in a specific jurisdiction

GLOSSARY OF TECHNICAL TERMS

“drug-drug interaction study” or “DDI study”	studies where the investigational drug is co-administered with known enzymatic inhibitor or substrate drugs
“First Catalogue of Rare Diseases”	the first list of 121 rare diseases (《第一批罕見病目錄》) jointly released by the National Health Commission (國家衛生健康委員會), the Ministry of Science and Technology (科學技術部), the Ministry of Industry and Information (工業和信息化部), the NMPA, and the National Administration of Traditional Chinese Medicine (國家中醫藥管理局) in China on May 11, 2018
“first-in-human”	the initial clinical trials conducted in human subjects after preclinical research and animal testing
“five-year survival rate”	a type of survival rate used to estimate the prognosis of a particular disease, referring to the percentage of patients who are still alive five years after cancer diagnosis
“GCP”	good clinical practice, an international set of guidelines that helps make sure that the results of a clinical trial are reliable and that the patients are protected. GCP covers the way a clinical trial is designed, conducted, performed, monitored, audited, recorded, analyzed, and reported
“GI intolerance”	gastrointestinal intolerance
“GLP”	Good Laboratory Practice, a quality system of management controls for research laboratories and organizations to try to ensure the uniformity, consistency, reliability, reproducibility, quality and integrity of chemical and pharmaceuticals non-clinical safety tests
“GMP”	Good Manufacturing Practice, a quality system enforced by relevant regulatory authorities, such as the FDA, to ensure that the products produced meet specific requirements for identity, strength, quality and purity
“HBV”	hepatitis B virus
“HCP”	healthcare professional
“Hepatitis B”	hepatitis B, an infectious disease caused by the HBV that affects the liver
“HREC”	Human Research Ethics Committee
“ICH”	the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
“ICU”	intensive care unit

GLOSSARY OF TECHNICAL TERMS

“ILD”	interstitial lung disease, a group of many lung conditions which affect the interstitium, a part of your lungs
“IND”	Investigational New Drug, also known as clinical trial application in China
“ <i>in vitro</i> ”	Latin for “within the glass,” a study or experiment which is done in the laboratory within the confines of a test tube or laboratory dish
“ <i>in vivo</i> ”	Latin for “within the living,” studies in which the effects of various biological or chemical substances are tested on whole, living organisms including animals, humans and plants, as opposed to a partial or dead organism, or those done <i>in vitro</i>
“IPF”	idiopathic pulmonary fibrosis, a type of lung disease that results in scarring (fibrosis) of the lungs
“JSC”	Joint Steering Committee
“KOL”	key opinion leader
“liver fibrosis”	the formation of an abnormally large amount of scar tissue in the liver
“LRTI”	lower respiratory tract infection is acute infections in the lung or below the larynx, caused by virus, bacteria, mycoplasma, chlamydia, legionella and other microorganisms, such as bronchitis, tuberculosis, lung infections caused by respiratory syncytial virus (RSV), and pneumonia
“mAb”	a monoclonal antibody, an antibody made by cloning a unique white blood cell
“mass balance study”	studies to understand how investigational drugs are absorbed, metabolized and excreted after dosing
“NDA”	new drug application
“NIH”	US National Institutes of Health
“NRDL”	China’s National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (《國家基本醫療保險、工商保險和生育保險藥品目錄》), or the National Reimbursement Drug List
“office action”	the examination letter issued by the CNIPA with respect to the substance examination for a pending patent application

GLOSSARY OF TECHNICAL TERMS

“PD”	pharmacodynamic
“PF-ILD”	progressive fibrosing interstitial lung disease, a group of fibrosing lung diseases characterized by progressive deterioration in lung function, physical performance, and quality of life in patients
“phase I clinical trial”	a study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its effectiveness
“phase II clinical trial”	a study in which a drug is administered to a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product for specific targeted diseases, and determine dosage tolerance and optimal dosage
“phase III clinical trial”	a study in which a drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to provide adequate information for the product’s labeling
“PhD”	doctor of philosophy
“PI”	principal investigator
“PICU”	pediatric intensive care
“PK”	pharmacokinetics
“QD”	once a day
“R&D”	research and development
“RNA”	ribonucleic acid, a nucleic acid present in all living cells. Its principal role is to act as a messenger carrying instructions from DNA for controlling the synthesis of proteins, although in some viruses RNA rather than DNA carries the genetic information
“RSV”	respiratory syncytial virus, a common respiratory virus that usually causes mild, cold-like symptoms
“The Scripps Research Institute”	a nonprofit American medical research facility that focuses on research and education in the biomedical sciences
“TID”	three times a day
“WBCS”	Wang’s bronchiolitis signs & symptoms score, an indicator to assess the severity of symptoms for a disease